NCT06063681View on ClinicalTrials.gov

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced / Metastatic Solid Tumor
Interventions
DRUG

SR-8541A

orally administered ENPP1 inhibitor

DRUG

Immune checkpoint inhibitor (ICI)

The ICI will be either nivolumab or pembrolizumab.

Trial Locations (3)

2031

RECRUITING

Scientia Clinical Research Ltd, Randwick

3168

RECRUITING

Monash Health, Clayton

3199

RECRUITING

Peninsula & South Eastern Haematology & Oncology Group, Frankston

Sponsors
All Listed Sponsors
lead

Stingray Therapeutics

INDUSTRY

NCT06063681 - A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter